Beginner-friendly guides grounded in peer-reviewed research. Compare prices, understand the science, and research smarter.
BioAge's BGE-102, an oral NLRP3 inhibitor, drove ≥85% median hsCRP reductions in a Phase 1 obesity cohort. The honest read — the data, the CANTOS precedent, the crowded NLRP3 race, and what it means (and doesn't) for inflammaging.
In a 2025 Science study, scientists restored regenerative wound healing in mice by switching ALDH1A2 back on — the enzyme that makes retinoic acid. Here's the honest science, plenty of sources, and what it does (and doesn't) mean for healing.
A generative-AI-designed drug just published Phase 2a human data in Nature Medicine. Here's the honest breakdown of Insilico Medicine's rentosertib, what AlphaFold actually changed, how AI is being used to design new peptides — and why your semaglutide was not AI-designed.
"Lab-tested" is a claim; a verifiable COA is proof. The 90-second checklist to confirm a peptide vendor's Certificate of Analysis — named lab, batch match, and lab-portal verification.
Fractyl's Rejuva (RJVA-001) is an experimental AAV gene therapy designed to make your own pancreas produce GLP-1 — a potential one-time alternative to weekly semaglutide. The mechanism, the preclinical data, the May 2026 first-in-human authorization, and the honest caveats about a treatment you can't undo.
RapidFulfillment is PeptidePrices' fulfillment and cold-chain logistics partner for research peptide brands — RUO peptide fulfillment, white-label dropshipping, and cold-chain logistics. Mention PeptidePrices for $300 off your fulfillment deposit.
RLS-1496 is Rubedo Life Sciences' first-in-class topical GPX4 modulator — a cream designed to clear senescent 'zombie' skin cells via ferroptosis. The Phase 1 and Phase 1b/2a data across psoriasis, atopic dermatitis, photoaging and actinic keratosis (a company-reported 46% lesion drop in 4 weeks), the 'senoadaptive' thesis, and the honest caveats.
VERVE-102 is a single-infusion gene-editing therapy that permanently switches off the PCSK9 gene to lower LDL cholesterol. The Heart-2 trial data, the VERVE-101 safety scare, the $1.3B Lilly buyout, and the honest caveats about a treatment you can't undo.
The ADA's 86th Scientific Sessions (June 5–8, 2026) dumped the year's biggest GLP-1 data: retatrutide's ~28% weight loss, CagriSema's first diabetes trials, and orforglipron's oral readout. A plain-English roundup — including the caveats.
BPC-157 has a huge, impressive animal-research literature and almost no human-trial data. Both are true. Here's exactly what's been published in people — the PL-14736 program, the registered-but-unpublished trial — and why the gap matters.
On Sept 19, 2025, SS-31 became FORZINITY — the first FDA-approved drug to directly target the mitochondria. But the approval is for an ultra-rare disease, and the broad anti-aging story is messier than the headline. What the cardiolipin-binding peptide actually does, and doesn't.
GLP-1s are no longer just diabetes and weight-loss drugs. A clear-eyed map of what's actually FDA-approved (heart, sleep apnea, MASH), what has strong trial data (kidney), and what has failed or is still hype (Alzheimer's, addiction).
Enlicitide (Merck's former MK-0616) is a once-daily cholesterol pill that's really an oral macrocyclic peptide — engineered to survive the gut. The Phase 3 CORALreef data, the empty-stomach catch, and what it signals for oral peptide drugs.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews 7 peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) for the 503A compounding list, with 5 more by early 2027. Here's what the hearing means, and what it doesn't.
Orforglipron (Foundayo) is the first oral GLP-1 approved for weight loss, and, surprisingly, it's a non-peptide small molecule, not a peptide. Here's how it works, the ATTAIN trial numbers, and how it stacks up against injectable semaglutide and tirzepatide.
Three credible voices, cardiologist Eric Topol, Peter Attia, and Paul Saladino, have pushed back on the peptide boom. Here's where they actually converge: the human-trial evidence gap, the GLP-1 exception, and the gray-market quality problem.
Dr. Paul Saladino's YouTube breakdown of peptides, GLP-1s, BPC-157/TB-500, GH secretagogues, melanotan, sorted into what's effective, what's risky, and why he argues there's no biological free lunch. We separate his verifiable points from his strong opinions.
A clear, fact-checked breakdown of the Huberman Lab peptides episode with Dr. Abud Bakri — BPC-157, GLP-1s, the Russian bioregulators, the thymus, GH secretagogues, and the gray-market reality. We separate the established science from the anecdotes.
Eli Lilly is fighting the FDA over whether retatrutide is a small-molecule drug or a biologic, a distinction that turns on amino-acid counting and could reshape competition, compounding, and the obesity-drug market. Here's what's actually at stake.
What is BPC-157? Learn how this research peptide works, what the research says, and how to compare prices across vendors — all in one place.
What is retatrutide? Discover how this triple-agonist research peptide works, what the clinical data shows, and how to compare prices across vendors.
What is NAD+? Learn how this research molecule works, what the science says about aging and metabolism, and how to compare NAD+ prices across vendors.
What is tesamorelin? Learn how this growth hormone-releasing research peptide works, what the FDA data shows, and how to compare prices across vendors.
What is TB-500? Learn how this research peptide works, what the science says about tissue repair, and how to compare TB-500 prices across vendors.
What is MOTS-c? Learn how this mitochondrial-derived peptide works, what the research says about metabolism and aging, and how to compare prices across vendors.
What is Semax? Learn how this ACTH-derived nootropic peptide works, what the clinical research shows for cognition and neuroprotection, and how to compare prices.
What is Selank? Learn how this tuftsin-derived anxiolytic peptide works, what clinical research shows for anxiety and stress, and how to compare prices across vendors.
What is CJC-1295? Learn how this GHRH analogue works, the key differences between With DAC and No DAC variants, and how to compare prices across vendors.
What is ipamorelin? Learn how this selective growth hormone-releasing peptide works, what clinical research shows, and how to compare ipamorelin prices across vendors.
Retatrutide vendor comparison for 2026. Per-mg pricing, COA notes, and what to look for before buying research-grade retatrutide.
Where to find the cheapest research-grade semaglutide in Q2 2026, plus a COA checklist for verifying a sema vendor before buying.
Six concrete criteria for checking whether a peptide vendor is trustworthy — named labs, batch COAs, endotoxin, address, track record, reviews.
BPC-157 vs TB-500 — the two most-researched recovery peptides. We break down the mechanisms, evidence, side-effect profiles, and current vendor pricing for each.
Looking at peptides for joint pain or tendon recovery? We rank the 7 most-researched options by evidence quality, side-effect profile, and current 2026 vendor pricing.
Semaglutide vs Tirzepatide vs Retatrutide — three generations of GLP-1 weight-loss peptides compared on efficacy, side effects, FDA status, and current 2026 vendor pricing.
The 8 best-researched peptides for women, ranked by evidence base and current vendor pricing. Covers GLP-1s for weight loss, GHK-Cu for skin, BPC-157 for recovery, and more.
PT-141 is the only FDA-approved peptide for sexual dysfunction. We break down the mechanism, evidence base, side effects, dosing patterns, and current vendor pricing.
